{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T20:17:12Z","timestamp":1783541832291,"version":"3.55.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018693","name":"HORIZON EUROPE Framework Programme","doi-asserted-by":"publisher","award":["HORIZON-MISS-2021-CANCER-02"],"award-info":[{"award-number":["HORIZON-MISS-2021-CANCER-02"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"HORIZON EUROPE Framework Programme","doi-asserted-by":"publisher","award":["101096667"],"award-info":[{"award-number":["101096667"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["GCB15152978SOEN"],"award-info":[{"award-number":["GCB15152978SOEN"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["LSHC-CT-2006-018702"],"award-info":[{"award-number":["LSHC-CT-2006-018702"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012513","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Cardiovasculares","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012513","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004963","name":"Seventh Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d'Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["2017_SGR_1134"],"award-info":[{"award-number":["2017_SGR_1134"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ad.2025.104517","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T16:26:17Z","timestamp":1764865577000},"page":"104517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Differences in Melanoma Between Patients With Locoregional Disease at Initial Diagnosis and Those Who Develop Locoregional Disease After Progression During Follow-Up"],"prefix":"10.1016","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1196-3174","authenticated-orcid":false,"given":"A.","family":"Luna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Alkhawaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Rizo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Carrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Malvehy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1337-9745","authenticated-orcid":false,"given":"S.","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4150-0522","authenticated-orcid":false,"given":"S.","family":"Podlipnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2025.104517_bib0130","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ejca.2022.03.008","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: update 2022","volume":"170","author":"Garbe","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ad.2025.104517_bib0135","series-title":"AJCC Cancer Staging Manual","first-page":"563","article-title":"Melanoma of the skin","author":"Gershenwald","year":"2017"},{"key":"10.1016\/j.ad.2025.104517_bib0140","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ejca.2022.04.018","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment \u2013 update 2022","volume":"170","author":"Garbe","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ad.2025.104517_bib0145","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/CLEP.S99021","article-title":"Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe \u2013 a systematic review of the literature","author":"Costa Svedman","year":"2016","journal-title":"CLEP"},{"key":"10.1016\/j.ad.2025.104517_bib0150","doi-asserted-by":"crossref","first-page":"adv00502","DOI":"10.2340\/00015555-3832","article-title":"Initial stage of cutaneous primary melanoma plays a key role in the pattern and timing of disease recurrence","volume":"101","author":"Ertekin","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2025.104517_bib0155","doi-asserted-by":"crossref","first-page":"15945","DOI":"10.1002\/cam4.6234","article-title":"A real-world study of adjuvant anti-PD-1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations","volume":"12","author":"Sun","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.ad.2025.104517_bib0160","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2025.104517_bib0165","doi-asserted-by":"crossref","first-page":"e1058037","DOI":"10.1080\/2162402X.2015.1058037","article-title":"Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma\u2014an exclamation sign with a question mark","volume":"4","author":"Kroemer","year":"2015","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ad.2025.104517_bib0170","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2025.104517_bib0175","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2025.104517_bib0180","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ad.2025.104517_bib0185","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/S1470-2045(18)30106-2","article-title":"Adjuvant vemurafenib in resected BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"19","author":"Maio","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ad.2025.104517_bib0190","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jaad.2016.02.1229","article-title":"Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: a prospective cohort study","volume":"75","author":"Podlipnik","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.104517_bib0195","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1371\/journal.pmed.0040297","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration","volume":"4","author":"Vandenbroucke","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.ad.2025.104517_bib0200","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3390\/genes14051021","article-title":"The genomic landscape of melanoma and its therapeutic implications","volume":"14","author":"Yang","year":"2023","journal-title":"Genes"},{"key":"10.1016\/j.ad.2025.104517_bib0205","article-title":"Telomere length and survival in primary cutaneous melanoma patients","volume":"8","author":"Rachakonda","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.ad.2025.104517_bib0210","doi-asserted-by":"crossref","first-page":"e0281487","DOI":"10.1371\/journal.pone.0281487","article-title":"TERT expression is associated with metastasis from thin primaries, exhausted CD4+ T cells in melanoma and with DNA repair across cancer entities","volume":"18","author":"Kuhn","year":"2023","journal-title":"PLOS ONE"},{"key":"10.1016\/j.ad.2025.104517_bib0215","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/cancers16020287","article-title":"The 31-gene expression profile test outperforms AJCC in stratifying risk of recurrence in patients with stage i cutaneous melanoma","volume":"16","author":"Podlipnik","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.ad.2025.104517_bib0220","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.3390\/ijms23116001","article-title":"MITF in normal melanocytes cutaneous and uveal melanoma: a delicate balance","volume":"23","author":"Gelmi","year":"2022","journal-title":"IJMS"},{"key":"10.1016\/j.ad.2025.104517_bib0225","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.3390\/cancers15123147","article-title":"Tumor microenvironment as a therapeutic target in melanoma treatment","volume":"15","author":"Kharouf","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ad.2025.104517_bib0230","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00418-021-02052-2","article-title":"Exosomes produced by melanoma cells significantly influence the biological properties of normal and cancer-associated fibroblasts","volume":"157","author":"Strnadov\u00e1","year":"2022","journal-title":"Histochem Cell Biol"},{"key":"10.1016\/j.ad.2025.104517_bib0235","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3390\/jpm13020221","article-title":"PD-L1 CD4+, and CD8+ tumor-infiltrating lymphocytes (TILs) expression profiles in melanoma tumor microenvironment cells","volume":"13","author":"Caraban","year":"2023","journal-title":"JPM"},{"key":"10.1016\/j.ad.2025.104517_bib0240","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1158\/1078-0432.CCR-15-1714","article-title":"PD-L1 negative status is associated with lower mutation burden, differential expression of immune-related genes, and worse survival in stage III melanoma","volume":"22","author":"Madore","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ad.2025.104517_bib0245","doi-asserted-by":"crossref","first-page":"1451103","DOI":"10.3389\/fimmu.2024.1451103","article-title":"Machine learning-based identification of an immunotherapy-related signature to enhance outcomes and immunotherapy responses in melanoma","volume":"15","author":"Deng","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.ad.2025.104517_bib0250","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12943-018-0757-5","article-title":"Liquid biomarkers in melanoma: detection and discovery","volume":"17","author":"Lim","year":"2018","journal-title":"Mol Cancer"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731025007860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731025007860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T19:26:11Z","timestamp":1783538771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731025007860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0001731025007860"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2025.104517","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Differences in Melanoma Between Patients With Locoregional Disease at Initial Diagnosis and Those Who Develop Locoregional Disease After Progression During Follow-Up","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2025.104517","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"104517"}}